Inovio Pharmaceuticals, Inc.

INO Healthcare Biotechnology

Inovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024. In the quarter to June 2026, revenue fell 83.2%, EPS grew 88.5% and free cash flow grew 13.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.99 0.05 −4.81%
Market cap
$107.5M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
1/9
Altman Z
−36.80
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
61.12 97.83 153.11 315.24 448.44 471.17 94.20 87.81 138.36 124.60
Total non-current assets
13.19 15.37 17.84 33.29 47.50 68.60 49.75 43.30 48.88 49.11
Total Assets
74.31 113.20 170.95 348.53 495.94 539.77 143.95 131.11 187.24 173.71
Total current liabilities
43.67 35.33 42.57 96.87 65.74 41.71 31.99 35.30 35.41 43.82
Total non-current liabilities
6.55 9.37 11.03 29.30 30.53 36.93 106.56 8.78 9.35 6.51
Total liabilities
50.21 44.69 53.60 126.17 96.27 78.63 138.55 44.08 44.75 50.33
Common Equity (Total)
24.10 68.50 117.35 222.36 399.67 461.14 5.40 87.03 142.49 123.38
Shareholders Equity (Total)
24.10 68.50 117.35 222.36 399.67 461.14 5.40 87.03 142.49 123.38
Total Debt
— — — 16.61 14.96 18.66 77.02 — — —

Show all line items

In millions of $ except per-share values · columns are period end dates